ArticleMaterials today. Bio2025
Immuno-protective cationic ginsenoside Rb1 vesicles for macrophage-mediated targeted therapy of inflammatory diseases.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ginsenoside Rb1 ameliorates endothelial dysfunction in sepsis: Targeting the RhoA/ROCK pathway to modulate mitochondrial homeostasis and inflammation.Journal of ginseng research · 2026Article
- A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury.Bioactive materials · 2026Article
- Targeting Ferroptosis in Sepsis: Therapeutic Potential and Mechanisms of Natural Products and Traditional Chinese Medicine.Journal of inflammation research · 2026Review
- Selective JAK2 inhibition by TG101209 reprograms macrophage polarization and alleviates acute lung injury.Frontiers in immunology · 2026Article
- Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory diseases (IDs), characterized by chronic inflammation, are linked to conditions such as bacterial and viral infections, arthritis, and neurodegenerative disorders. Current treatments offer only temporary relief, highlighting the need for more effective therapies. Ginsenoside Rb1 (Rb1), with potent anti-inflammatory and antioxidant properties, can self-assemble into nanoparticles. To enhance targeted therapy for IDs, this study explores the effects of cationic modifications on Rb1 self-assemblies (GRb1). Among the various modifications, polyethylenimine (PEI) (GRb1@PEI) is the most effective at enhancing GRb1's ability to specifically target macrophages. In a murine model of LPS-induced sepsis-related acute lung injury (ALI), PEI facilitates the delivery of Rb1 to sites of inflammation. There, Rb1 inhibits the TNF-α signaling pathway, which helps normalize inflammatory markers and reduce immune cell recruitment. Additionally, GRb1@PEI serves as a multifunctional carrier for antibiotics with diverse physicochemical properties, enhancing bacterial clearance and alleviating inflammation and immune responses in blood infection-associated ALI and bacterial pneumonia models. Among four cationic polymer-modified GRb1 variants, this study demonstrates that GRb1@PEI is the most efficient multifunctional nanocarrier for targeted anti-inflammatory therapy of inflammatory diseases, providing important guidance for future therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.